Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Paruzzo

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Nature Protocols|July 27, 2025
Manufacturing of CRISPR-edited primary mouse CAR T cells for cancer immunotherapyPuneeth Guruprasad, Ranjani Ramasubramanian, Siena Nason, et al.
Haematologica|February 6, 2025
Non-tuberculous mycobacterial infections following teclistamab in multiple myelomaMatthew Ho, Luca Paruzzo, Janna Minehart, et al.
Cytotherapy|March 14, 2024
Streamlined measurement of chimeric antigen receptor T-cell concentration, size, viability and two-color phenotyping during manufacturingRaymone Pajarillo, Luca Paruzzo, Alberto Carturan, et al.
Blood Cancer Journal|November 4, 2025
Outcomes of relapse after teclistamab therapy in multiple myelomaKyle L Yu, Matthew Ho, Luca Paruzzo, et al.
Journal for Immunotherapy of Cancer|June 25, 2025
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapyRyan J Sullivan, Anthony R Cillo, Robert L Ferris, et al.
Transplantation and Cellular Therapy|March 17, 2024
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell LymphomaElise A Chong, Emeline R Chong, Dylan Therwhanger, et al.
Journal of Hematology & Oncology|April 21, 2024
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucelGuido Ghilardi, Luca Paruzzo, Vrutti Patel, et al.
The New England Journal of Medicine|June 24, 2026
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell LymphomasMarco Ruella, Luca Paruzzo, Emeline R Chong, et al.
Blood|September 8, 2023
Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapiesZhiwei Ang, Luca Paruzzo, Katharina E Hayer, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2023
Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapiesZhiwei Ang, Luca Paruzzo, Katharina E Hayer, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Nature Protocols|July 27, 2025
Manufacturing of CRISPR-edited primary mouse CAR T cells for cancer immunotherapyPuneeth Guruprasad, Ranjani Ramasubramanian, Siena Nason, et al.
Haematologica|February 6, 2025
Non-tuberculous mycobacterial infections following teclistamab in multiple myelomaMatthew Ho, Luca Paruzzo, Janna Minehart, et al.
Cytotherapy|March 14, 2024
Streamlined measurement of chimeric antigen receptor T-cell concentration, size, viability and two-color phenotyping during manufacturingRaymone Pajarillo, Luca Paruzzo, Alberto Carturan, et al.
Blood Cancer Journal|November 4, 2025
Outcomes of relapse after teclistamab therapy in multiple myelomaKyle L Yu, Matthew Ho, Luca Paruzzo, et al.
Journal for Immunotherapy of Cancer|June 25, 2025
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapyRyan J Sullivan, Anthony R Cillo, Robert L Ferris, et al.
Transplantation and Cellular Therapy|March 17, 2024
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell LymphomaElise A Chong, Emeline R Chong, Dylan Therwhanger, et al.
Journal of Hematology & Oncology|April 21, 2024
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucelGuido Ghilardi, Luca Paruzzo, Vrutti Patel, et al.
The New England Journal of Medicine|June 24, 2026
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell LymphomasMarco Ruella, Luca Paruzzo, Emeline R Chong, et al.
Blood|September 8, 2023
Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapiesZhiwei Ang, Luca Paruzzo, Katharina E Hayer, et al.
Biorxiv : the Preprint Server for Biology|August 30, 2023
Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapiesZhiwei Ang, Luca Paruzzo, Katharina E Hayer, et al.
Pageof 5